Patent Description:
Diabetes has reached epidemic proportions in much of the western world and is a serious and growing public health concern in many developing economies. Globally, there are approximately <NUM> million people with diabetes and that number is expected to reach <NUM> million by <NUM> (<NPL>.

Diabetes complications are usually associated with chronically elevated blood glucose levels (hyperglycemia), which result in heart, kidney and eye diseases, amputations and neurological impairment. Unfortunately, medications (e.g., insulin) used to treat diabetes-related hyperglycemia to reduce blood sugar levels often cause the patient's blood sugar level to drop too low and lead to hypoglycemia (low blood sugar).

Depending on the severity of the episode, hypoglycemia causes a wide range of physical problems ranging from weakness, dizziness, sweating, chills and hunger to more serious symptoms including blurred vision, behavior change, seizures, coma and even death. In addition to the physical effects of hypoglycemia, there are significant psychological effects including embarrassment, fear of another episode, high levels of anxiety and low levels of overall happiness that adversely affect glucose control and quality of life (Deary, <NUM>).

Glucagon is a highly effective treatment for severe hypoglycemia both outside and within the hospital setting. Historically, glucagon was available only as a powder that must be mixed with a diluent immediately prior to administration by injection. Although this is a procedure that would be relatively easy for people with diabetes who inject insulin, they are not treating themselves because, by definition, severe hypoglycemia is a hypoglycemic episode in which the patient requires third party assistance (Cryer, <NUM>). For any non-medical person who is confronted with an emergency situation in which a patient with diabetes is in a hypoglycemic coma or suffering hypoglycemia-related convulsions, reconstitution and injection of the current injectable glucagon is a complex and daunting procedure that is fraught with potential for errors.

Recently, the U. Food and Drug Administration (FDA) approved intranasal glucagon for the treatment of severe hypoglycemia. Compared to intramuscular glucagon that must be reconstituted and injected, intranasal glucagon may be ready-to-use in a single, fixed dose without requiring reconstitution or injection. The associated intranasal device is also easy to use and portable in case of emergency.

Nasal delivery devices are known for dispensing media such as powders and fluids for discharge into the body. Such device includes an actuator, an outlet nozzle, and a drug drive system that is activated by the actuator that causes the media to discharge from the outlet nozzle. There is a desire to continue to improve the sturdiness and measures to prevent accidental actuation of such nasal delivery devices. This sturdiness would also need to be balanced with a continued need for ease in operation. It is an object of the present invention to provide such an improved nasal delivery device.

<CIT> B <NUM> discloses a disposable atomizer with a dispenser unit. The unit contains a media container which also forms the pump chamber and which is sealed by a piston-type stopper. When activated, the piston-type stopper is punctured by a hollow needle. The outlet nozzle surrounds the dispenser unit to a large extent. The dispenser unit can be introduced into an activating unit. The activating unit is pin-shaped with a loading chamber. The dispenser unit is held in place by an activating push rod which can be longitudinally displaced when activated by turning and is prestressed by a spring. The dispenser is activated by a trigger device.

<CIT> and <CIT> both disclose a monodose nasal sprayer. The sprayer utilizes a friction held piston that fires automatically upon full depression of the firing cap. The drive spring does not release to fire the piston until after the spring is fully compressed because the force required to overcome the frictional force between said high friction engaging surface of the piston and the piston shaft is greater than the force required to compress said spring. A user may procure a monodose of medicine by (i) unlocking a child resistant locking mechanism; (ii) applying compressive force against the firing cap so as to first compress the spring and then to push the piston out of an piston engaging friction area such that the spring causes the distal end of the piston to break the medicine container to drive medicine through the spray nozzle in a manner that is user independent as to dosage amount and dosage speed of delivery.

<CIT> discloses a manually operated monodose nasal sprayer device. The nasal sprayer utilizes a piston that fires automatically upon full depression of the firing cap. The drive spring does not fire the piston until fully compressed because the force required to break a puncturable medicine container is greater than to compress the spring. The piston height is greater than the firing cap and central member height combined so that after the spring is fully compressed, the piston punctures the medicine container. The spring then releases, pushing the piston toward the nozzle. A user procures medicine from the device by (i) unlocking a child resistant lock; (ii) applying compressive force against the firing cap to compress the spring and to push the piston to puncture the medicine container, then the spring causes the distal end of the piston to drive medicine through the spray nozzle independent of the user as to dosage amount and speed of delivery.

Further aspects and preferred embodiments of the invention are defined in the dependent claims. Any aspects, embodiments and examples of the present disclosure which do not fall under the scope of the appended claims are provided for illustrative purposes.

There is hereinafter disclosed a nasal delivery device with a device body that includes a trigger end and an outlet end. The nasal delivery device also includes a trigger assembly coupled to the trigger end of the device body, a drug container supported by the device body, and a springloaded activator assembly supported by the device body and disposed between the trigger assembly and the drug container.

There is also disclosed a the nasal delivery device having a device body including a trigger end and an outlet end; a trigger assembly coupled to the trigger end of the device body; an output assembly including a drug container supported by the device body and including a medication, a first seal and an outlet seal; and an elastic activator device configured to bias the push rod to open the first seal and to drive movement of the drug container towards the outlet end to open the outlet seal and expel the medication from the outlet end.

There is also a disclosure of a the nasal delivery device having a device body including a trigger end and an outlet end; a trigger assembly coupled to the trigger end of the device body and including at least one prong and a safety rod; an output assembly including a drug container supported by the device body, a first seal and an outlet seal; and an activator assembly including an elastic activator device and at least one latch; and wherein upon activation of the trigger assembly, the at least one prong and the safety rod move towards the outlet end and the safety rod moves clear of the at least one latch and the at least one prong engages the at least one latch to release the elastic activator device.

The following also includes a disclosure of a nasal delivery device having a device body including a trigger end and an outlet end; a trigger assembly coupled to the trigger end of the device body; a drug container supported by the device body; and an activator assembly operably coupled to the trigger assembly and including a push rod and an elastic activator device, the activator assembly has a series of configurations which include a latched configuration in which the activator assembly is latched relative to the device body and the elastic activator device is loaded; an unlatched configuration in which the activator assembly is released from the device body; and a delivery configuration in which the elastic activator device is axially moved toward the outlet end to drive the push rod into engagement with the drug container thereby moving the drug container towards the outlet end to expel the medication out from the outlet end.

The above mentioned and other features of this present disclosure, and the manner of attaining them, will become more apparent and the invention itself will be better understood by reference to the following description of embodiments of the present disclosure taken in conjunction with the accompanying drawings, wherein:.

Corresponding reference characters indicate corresponding parts throughout the several views. Although the exemplification set out herein illustrates embodiments of the present disclosure, in several forms, the embodiments disclosed below are not intended to be exhaustive or to be construed as limiting the scope of the invention to the precise forms disclosed.

For the purpose of promoting an understanding of the principles of the invention, reference will now be made to the embodiments illustrated in the drawings and specific language will be used to describe the same. Any alterations and further modifications in the described embodiments, and any further applications of the principles of the invention as described herein are contemplated as would normally occur to one skilled in the art to which the invention relates. One embodiment of the invention is shown in great detail, although it will be apparent to those skilled in the relevant art that some features that are not relevant to the present invention may not be shown for the sake of clarity.

The proposed designs are for a nasal delivery device. The designs have advantages such as, for example, the use of two seals in the device instead of four seals found in some devices. Another advantage of some of the embodiments may be reduced actuation force since the dosing energy is supplied by a loaded compression spring. The actuation force will be comparatively low because it is used to release the spring and does not need to provide the energy to expel the drug media. Another advantage of some of the embodiments may be the provision of a lock/safety feature to prevent inadvertent actuation by rough handling or shipping. Another advantage may be a housing snap arrangement to provide a locking feature to maintain the snap fit joint between the nozzle outlet and the device housing. Another advantage of some of the embodiments may be the provision of a drug container with a seal piercing design to allow the dosing spring to push the container through the seal and to expel the drug as the container stops.

<FIG> illustrates a first exemplary embodiment of a nasal delivery device <NUM>. As shown in <FIG>, nasal delivery device <NUM> includes a device housing or body <NUM>, a trigger assembly <NUM>, an activator assembly <NUM>, and an output assembly <NUM>, each of which is described further below. The components are disposed relative to one another along a common axis AA.

Device body <NUM> includes a trigger end <NUM> (which may be referred to herein as an "upper" end based on the orientation of <FIG>) and an outlet end <NUM> (which may be referred to herein as a "lower" end based on the orientation of <FIG>). Other orientational terms such as "vertical", "horizontal", "above", "below", etc. are used based on the orientation of <FIG>. However, it is understood that the device body <NUM> can be used in other orientations.

Between the trigger end <NUM> and the outlet end <NUM>, device body <NUM> includes a finger grasp <NUM> configured to be grasped by an operator. Finger grasp <NUM> may take any number of forms and sizes, and may have a cross-sectional area greater than the cross-sectional area of the device body <NUM> as shown. For example, finger grasp <NUM> may be a single circular flange surrounding the entire device body <NUM>, it may be distinct flanges extending outwardly from opposing sides of device body <NUM>, and/or it may be shaped to surround a finger of the operator.

Near the trigger end <NUM> of device body <NUM>, device body <NUM> includes one or more internal trigger assembly catches <NUM>. Trigger assembly catches <NUM> engage with a portion of trigger assembly <NUM>. More specifically, trigger assembly catches <NUM> each include a radially outward extending lower lip <NUM> that prevents trigger portion <NUM> from being detached from nasal delivery device <NUM>, as discussed in greater detail below. Catches in the position shown in the figures can be extensions from an internal wall 10a of the device body as part of the injection molding and/or may be a separate component fixedly secured to the internal of the device body.

Continuing downward from trigger assembly catches <NUM>, device body <NUM> includes an internal shoulder <NUM>. Internal shoulder <NUM> may be a single circular shoulder <NUM> or multiple individual shoulders <NUM> extending radially inward from the internal wall 10a. The internal shoulder <NUM> may interact with both the trigger portion <NUM> on one side and the activator assembly <NUM> on the other side, as discussed in greater detail below.

Device body <NUM> also includes an activator catch <NUM>. Activator catch <NUM> could include a single circular catch <NUM> or multiple individual catches <NUM>. Activator catch <NUM> extends radially inward from internal wall 10a of device body <NUM> and may be angled at least partially axially towards the trigger end <NUM> of device body <NUM>. The angled orientation of activator catch <NUM> may allow activator catch <NUM> to engage with a portion of activator assembly <NUM> to keep activator assembly <NUM> in a latched configuration until activator assembly is unlatched. Activator assembly <NUM> and its various configurations will be discussed in greater detail below.

At the outlet end <NUM>, device body <NUM> includes a nozzle <NUM> from which the drug is dispensed. Device body <NUM> also includes a drug container stop <NUM> that extends radially inward from device body <NUM> around the nozzle <NUM>. Stop <NUM> may be angled at least partially axially towards the trigger end <NUM> of device body <NUM>. The angled orientation of drug container stop <NUM> may allow drug container stop <NUM> to prevent a portion of output assembly <NUM> from expelling from nasal delivery device <NUM>. The operation of outlet portion <NUM> of nasal delivery device <NUM> will be discussed in further detail below.

Returning towards the trigger end <NUM> of device body <NUM>, a depressed button catch receiver <NUM> is provided, shown as a notch defined in the device body. Depressed button catch receiver <NUM> is a depressed portion of device body <NUM> that receives a portion of trigger assembly <NUM> when trigger assembly <NUM> is depressed.

The trigger assembly <NUM> is coupled to the trigger end <NUM> of device body <NUM>. Trigger assembly <NUM> includes a button <NUM> that extends axially beyond the trigger end <NUM> of device body <NUM> for access by the operator. Button <NUM> defines an upper wall, on which the operator depresses, and a downwardly extending sidewall extending from the upper wall that encloses a button cavity. Button <NUM> includes at least one trigger assembly latch <NUM>. Latch <NUM> may be incorporated into the sidewall or may be segmented from the sidewall. In one example, trigger assembly latch <NUM> extends from the upper wall of button <NUM> axially into device body <NUM> toward the outlet end and ends with a radially inward extending lip <NUM>. Trigger assembly latch <NUM> can include a single continuous lip <NUM> or a plurality of individual lips <NUM>. Lips <NUM> of trigger assembly latch <NUM> engage trigger assembly catches <NUM> of device body <NUM> to prevent button <NUM> from being detached from nasal delivery device <NUM>, as noted above.

Button <NUM> also includes prongs <NUM>. Prongs <NUM> are located radially inward of and in spaced relationship with trigger assembly latches <NUM> and extend axially into device body <NUM> toward the outlet end from the upper wall. Prongs <NUM> end at their lowest point with angled ends <NUM>. In another example, the prongs <NUM> may be defined as a single internal cylindrical body extending from the upper wall.

Button <NUM> may further include a safety rod <NUM> optionally. Safety rod <NUM> is located radially inward of and in spaced relationship with both trigger assembly latch <NUM> and prongs <NUM>. Safety rod <NUM> extends axially from a central portion of upper wall of button <NUM> along the axis AA toward the outlet end and into device body <NUM> axially beyond the latch <NUM> and prongs <NUM>. In an embodiment, the safety rod <NUM> has a constant cross-sectional area. In other embodiments, safety rod <NUM> can include two portions, a first, cross-sectionally narrow portion <NUM> having a second cross-sectional area W2 (see <FIG>) and a second, wide portion <NUM> comparted to the first portion <NUM> having a larger cross-sectional area W1 (see <FIG>). As shown in <FIG>, first portion <NUM> forms the stem of safety rod <NUM> and extends axially from button <NUM> toward the outlet end, while second portion <NUM> forms an enlarged end of safety rod <NUM> having a short and wide profile compared to first portion <NUM>. The function of the safety rod <NUM> will become apparent below.

Trigger assembly <NUM> also includes an elastic trigger device <NUM> (e.g., an axially compressible spring) that biases button <NUM> up and away from device body <NUM> and from activator assembly <NUM>. In the embodiment of <FIG>, elastic trigger device <NUM> surrounds the internal diameter of device body <NUM> and sits within a cylindrical chamber of device body <NUM> above internal shoulder <NUM>. Elastic trigger device <NUM> is shown axially disposed between internal shoulder <NUM> and the latch <NUM>. Elastic trigger device <NUM> of the embodiment of <FIG> biases button <NUM> through contact with internal shoulder <NUM> below and trigger assembly latch <NUM> above. By the biasing, the button has an initial extended configuration that is defined physically by engagement between lips <NUM> of trigger assembly latch <NUM> and trigger assembly catches <NUM>. Button is movable from the extended configuration to a fully depressed configuration when an axial force is applied to the upper wall of the button in an axial direction toward the outlet end that is greater than the biasing force of elastic trigger device <NUM>. When such a great force is applied, the lips <NUM> of trigger assembly latch <NUM> disengage from trigger assembly catches <NUM> as the button travels axially toward the output end relative to the device body.

Activator assembly <NUM> includes an activator plate <NUM> positioned interiorly within device body <NUM> and initially axially spaced from an upper surface 41a of a drug container housing <NUM> disposed in the device body to allow clearance for movement of the activator assembly within the device housing. Activator assembly <NUM> also includes a plurality of latches <NUM> that extend axially towards the trigger end <NUM> of device body <NUM> from activator plate <NUM>. The ends 31a of latches <NUM> engage with activator catch <NUM> of device body <NUM> to hold activator assembly <NUM> in a latched configuration and are configured to flex radially to disengage from the catch <NUM>. Activator assembly may also include an outer wall <NUM> extending axially toward trigger end and disposed radially outward of and in spaced relationship with latches <NUM>. As shown, outer wall <NUM> may be spaced radially inward from the outer edge of the activator plate to define a cylindrical chamber for an elastic activator device <NUM>.

Activator assembly <NUM> also includes elastic activator device <NUM> (e.g., an axially compressible spring) in contact with the outer edges of activator plate <NUM>, surrounding outer wall <NUM>, and the bottom of internal shoulder <NUM> of device body <NUM>, shown as axially aligned and opposite with elastic trigger device <NUM>. Elastic activator device <NUM> biases activator assembly <NUM> towards the outlet end of device body <NUM>. As shown in <FIG>, elastic activator device <NUM> is loaded while activator assembly <NUM> is in the latched position. The nature and function of elastic activator device <NUM> will be discussed in greater detail below.

Activator assembly <NUM> also includes a push rod <NUM> coupled to a central portion of activator plate <NUM> and extending axially towards the outlet end <NUM> of device body <NUM> along the axis AA. The shape and size of push rod <NUM> is configured for receipt in output assembly <NUM>. In one example, the push rod <NUM> and the safety rod <NUM> are in axial alignment along axis AA. Push rod <NUM> may have a tapered end.

Output assembly <NUM> may include a drug container housing <NUM> that is nested within device body <NUM> towards the outlet end <NUM> of device body <NUM>. In one embodiment, the housing <NUM> is a separate component nested in the device body <NUM>. In another embodiment, the configuration of housing <NUM> shown in the figures is part of the interior of the device body or integrally formed with the device body. Drug container housing <NUM> includes a hole <NUM> defined in an upper end of housing <NUM> that is closest to the trigger end <NUM> of device body <NUM> that may match the shape and size of push rod <NUM>. Hole <NUM> may be funnel shaped, having a wider upper end and a narrower lower end to help guide the end of push rod <NUM> to the upper end of the drug container <NUM>. Nested within drug container housing <NUM> is drug container <NUM>. Drug container <NUM> encloses a drug chamber <NUM> which contains a medication in powder or fluid form, such as, for example, insulin for treatment of diabetes, glucagon to prevent severe hypoglycemia, dihydroergotamine (DHE) for treatment of migraine, growth hormones, etc.. Drug container housing <NUM> also defines a first seal <NUM> in that it physically cooperates with drug container <NUM> preventing anything from entering drug container housing <NUM> through the hole <NUM> of drug container housing <NUM> and/or the drug container <NUM>. The first seal <NUM> may also retain the drug container <NUM> in a friction-fit arrangement with the drug container housing <NUM> or with the device body <NUM> (not shown) similar to an interior shaped like housing <NUM>. The drug container housing <NUM> includes an inner sealing portion <NUM>, for example, an inner radial surface of a diametric reduced neck region of housing <NUM>, contiguous with the lower end of the hole <NUM>, that is sized and shaped to sealably engage a portion <NUM> of the drug container <NUM>. For example, such portion <NUM> may be defined by an outer radial surface of a diametric head end. Portion <NUM> and portion <NUM> engage one another radially define the first seal <NUM> via an interference fit. Drug container housing <NUM> also includes an outlet seal <NUM> lining the bottom of drug container <NUM> as an axial end seal and preventing drug leakage and contamination from the outside environment. Outlet seal <NUM> can be a film such as foil seal, or any other sealant film material commonly used or known in the medical device field. Drug container housing <NUM> also contains a piercing portion <NUM> that is shaped and configured to pierce through or otherwise open the outlet seal <NUM>. Piercing portion <NUM> is shown as a tapered end of the drug container <NUM> where a portion of the wall extends further than another portion of the wall. The end of the piercing portion <NUM> is shown spaced from the outlet seal <NUM> pre-seal where the medication can be disposed between the outlet seal and up into the drug container <NUM>. When the drug container <NUM> slides along the inner wall of the drug container housing <NUM>, the end of piercing portion <NUM> is physically stopped by drug container stop <NUM>, which is shown as an annular recess defined along the inner wall 10a in close proximity to nozzle <NUM>. The dashed lines <NUM> is representative of the location of the outlet seal <NUM> after being pierced.

<FIG> depict several different configurations of nasal delivery device <NUM> and show various stages in the use of device <NUM>.

<FIG> shows nasal delivery device <NUM> in a latched configuration. In the latched configuration, trigger assembly <NUM> has an inactive configuration. Button <NUM> is biased in the extended configuration towards trigger end <NUM> of device body <NUM> by elastic trigger device <NUM>. Trigger assembly latches <NUM> are engaged with lip <NUM> of trigger assembly catch <NUM> and prevent button <NUM> from being removed from nasal delivery device <NUM>. Prongs <NUM> are axially spaced apart from latches <NUM> of activator assembly <NUM>. Also, latches <NUM> are engaged and latched onto activator catch <NUM> such that activator <NUM> is held up against the load of elastic activator device <NUM>. Safety rod <NUM> is in a raised position in the latched configuration, where second portion <NUM> of safety rod <NUM> is positioned radially between ends 31a of latches <NUM> of activator assembly <NUM>. In this raised position, second portion <NUM> of safety rod <NUM> inhibits the radial inward movement of ends 31a of latches <NUM> to prevent latches <NUM> from moving enough to disengage or unlatch from activator catch <NUM> in the event of accidental activation of activator assembly <NUM>, such as an accidental drop or other shock load.

<FIG> shows nasal delivery device <NUM> in an intermediate configuration. In the intermediate configuration, button <NUM> is depressed slightly and trigger assembly <NUM> moves down against the bias of elastic trigger device <NUM> toward its fully depressed configuration from its extended configuration. Trigger assembly latches <NUM> disengage from trigger assembly catch <NUM> (<FIG>). Prongs <NUM> begin to approach the ends 31a of latches <NUM> of activator assembly <NUM>. Due to the shape and angle of both prongs <NUM> and latch ends 31a, as prongs <NUM> move down and slidably engage latch ends 31a, prongs <NUM> push ends 31a of latches <NUM> radially inward and toward safety rod <NUM>. In the intermediate position, button <NUM> has not been depressed enough or is not at an axial position sufficient for unlatching, and second portion <NUM> of safety rod <NUM> still interferes with ends 31a of latches <NUM> and prevents latches <NUM> from completely unlatching from activator catch <NUM>.

<FIG> shows nasal delivery device <NUM> in an unlatched configuration in the moment before the stored energy in the compressed elastic activator device <NUM> (<FIG>) pushes activator assembly <NUM> down towards the outlet end <NUM>. In the unlatched configuration, button <NUM> has been moved to its fully depressed configuration towards the outlet end <NUM> of device body <NUM>. Fully depressing button <NUM> moves the wide, second portion <NUM> of safety rod <NUM> axially relative to latches <NUM> toward the outlet end to a clearance position as shown in <FIG> and moves the narrow, first portion <NUM> of safety rod <NUM> radially between ends 31a of latches <NUM>. Fully depressing button <NUM> also causes prongs <NUM> to contact activator catch <NUM> while pushing ends 31a of latches <NUM> radially inward away from activator catch <NUM>. Without interference from safety rod <NUM>, latches <NUM> are released radially from activator catch <NUM> to allow the preloaded elastic activator device to unload for axially driving the activator plate.

<FIG> shows nasal delivery device <NUM> in a delivery configuration. In this delivery configuration, the preloaded elastic activator device <NUM> (<FIG>) has unloaded its energy and applied an axial force on activator plate <NUM> of activator assembly <NUM> in the direction of the outlet end, which has pushed activator assembly <NUM> towards the outlet end <NUM> of device body <NUM>. As activator assembly <NUM> moves towards the outlet end <NUM> of device body <NUM>, push rod <NUM> enters the hole <NUM> of drug container housing <NUM>. As push rod <NUM> pushes into the head end of the drug container <NUM>, push rod <NUM> with sufficient axial force breaks the radial friction force of first seal <NUM> which allows drug container <NUM> to be loosened from drug container housing <NUM>. Push rod <NUM> continues to push axially toward the outlet end and apply an axial force on drug container <NUM> towards the outlet end <NUM> of device body <NUM>. As drug container <NUM> is pushed axially, piercing portion <NUM> on drug container <NUM> slices through outlet seal <NUM> of drug container housing <NUM>. Drug container <NUM> stops moving axially upon contacting the drug container stop <NUM>. However, because the outlet seal <NUM> of drug container <NUM> has been broken, the drug powder in drug chamber <NUM> continues to travel axially through the broken outlet seal <NUM>, through nozzle <NUM>, and toward the patient. The ability to deliver the drug using the energy of the elastic activator device <NUM> (<FIG>) that is converted to momentum in the medication to expel the medication from the outlet may avoid the need for compressed air inside the nasal delivery device <NUM>.

Nasal delivery device <NUM> is a single use drug delivery device. In order to determine whether a specific assembly of nasal delivery device <NUM> has been used or not, trigger assembly <NUM> stays in the depressed position after depression of trigger assembly <NUM> and activation of activator assembly <NUM>. In the embodiment of <FIG>, as button <NUM> of trigger assembly <NUM> is depressed, depressed button catch <NUM> engages with depressed button catch receiver <NUM> of device body <NUM>. Upon complete depression of button <NUM>, depressed button catch <NUM> and depressed button catch receiver <NUM> lock together in a snap-fit configuration preventing elastic trigger device <NUM> from resetting the position of trigger assembly <NUM>.

<FIG> illustrates a second exemplary embodiment of a nasal delivery device <NUM>'. The second nasal delivery device <NUM>' of <FIG> is similar to the first nasal delivery device <NUM> of <FIG>, with like reference numerals indicating like elements, except as described below. The second nasal delivery device <NUM>' includes an elastic trigger device <NUM>' similar to elastic trigger device <NUM>. However, elastic trigger device <NUM> is shown located beneath trigger assembly latches <NUM>' and axially spaced from elastic activation trigger toward the trigger end as shown in <FIG>, the elastic trigger device <NUM>' of <FIG> is a narrow spring located between an end portion <NUM>' of safety rod <NUM>' and activator plate <NUM>' of activator assembly <NUM>'. The elastic trigger device <NUM>' is shown disposed radially inward of the elastic activation trigger <NUM>' in a coaxial relationship. The elastic trigger device <NUM>' is shown disposed radially inward of latches <NUM>' in a coaxial relationship. Also, as button <NUM>' of trigger assembly <NUM>' is depressed, trigger assembly latches <NUM>' frictionally engage with the inner wall of device body <NUM>'. The frictional force applied between the inner wall of device body <NUM>' and trigger assembly latches <NUM>' is great enough to retain the button <NUM> in body <NUM>'. The operation of the device <NUM>' is similar to what is described related to device <NUM> in <FIG>. One advantage of the configuration of device <NUM>' may be that elastic trigger device <NUM>'may contribute as an additional axial force activation source for trigger <NUM>', in addition to force provided by the elastic activation trigger <NUM>'. To this end, as the button is depressed fully, the elastic trigger device <NUM>' is at least partially loaded as it is axially compressed, and when in the unlatched configuration, the stored energy in the elastic trigger device <NUM>' is applied directly to the activation plate <NUM>' to potentially create greater momentum in the medication to expel the medication from the outlet as a higher rate than in device <NUM>.

Claim 1:
A nasal delivery device comprising:
a device body including a trigger end and an outlet end;
a trigger assembly coupled to the trigger end of the device body, the trigger assembly including prongs extending axially from the trigger assembly toward the outlet end, and a safety rod extending axially from the trigger assembly toward the outlet end;
an output assembly including a drug container supported by the device body and configured to hold a medication, a first seal and an outlet seal; and
an activator assembly operably coupled to the trigger assembly and including:
a push rod which extends towards the drug container,
a plurality of latches extending axially away from the outlet end from the activator assembly, and
an elastic activator device configured to bias the push rod to open the first seal and to drive movement of the drug container towards the outlet end to open the outlet seal and to expel the medication from the outlet end,
wherein the device body further includes at least one activator catch, extending towards the trigger end at an angle and configured to support the plurality of latches of the activator assembly in the latched configuration; and
wherein, in response to the movement of the trigger assembly relative to the device body, the prongs engage the plurality of latches of the activator assembly to release the plurality of latches of the activator assembly from the at least one activator catch of the device body and transition the activator assembly from a latched configuration to an unlatched configuration to permit the elastic activator device to drive the activator assembly axially towards the first seal, wherein the first seal is defined by a radial friction fit between a portion of the drug container and the device body or a drug container housing,
wherein the safety rod has a first portion with a first cross-sectional area and a second portion with a second cross-sectional area that is smaller than the first cross-sectional area, wherein the first portion is disposed radially between the plurality of latches to inhibit radial movement of the latches when the activator assembly is in the latched configuration.